SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (80524)5/9/2000 12:31:00 AM
From: Spekulatius  Respond to of 132070
 
LGND management is not shareholder friendly
and hasn't build shareholder value. LGND stock has a dilution rate of about 20% per year with little revenue to show so far. Their science is good but their business acumen not.
CELG has an astute management but the stock is too expensive right now,IMHO. If you are looking for a cheap Biotech microcap with a (potentially) strong pipeline, check out NPSP.



To: Knighty Tin who wrote (80524)5/9/2000 9:50:00 AM
From: pater tenebrarum  Read Replies (1) | Respond to of 132070
 
MB, first of all, thanks for pointing UCL out to us. it has had a nice run so far. my question now is at what level you would consider taking profits on that one.

regards,

hb


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News